Actualités

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.

ImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

On July 29, UAE regulators approved ImmunityBio’s main cancer drug ANKTIVA for two indications, sparking a rally the next day.

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -13.42% and +69.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The UAE becomes Anktiva’s fifth regulatory jurisdiction, expanding its footprint to 34 countries and boosting ImmunityBio’s global push.

Investors are also watching for partnership or buyout catalysts as ImmunityBio expands Anktiva internationally and builds its global NK-cell platform.

ImmunityBio’s stock has surged 282.7% year to date, yet its overall valuation checks sit at a mixed 3 out of 6. This leaves investors weighing a powerful momentum story against signals that do not clearly flag the shares as cheap or expensive. The year to date gain of 282.7% suggests expectations around ImmunityBio have reset sharply higher. Fresh buyers are now paying a far richer price than they would have earlier in the year. Speculation around Anktiva’s potential role in bladder cancer...

J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.

Sheets Smith Wealth Management cut its IBRX stake by 7.2% to 512,572 shares.

Retail traders are watching to see whether ImmunityBio could announce preliminary Q2 revenue, with some speculating that demand for Anktiva could drive sales above $55 million.

The semi-annual reconstitution of the index, based on market capitalizations as of April 30, 2026, will take effect after the U.S. market close on Friday, June 26.

IBRX is already part of the Russell 2000, Russell 2500, and Russell 3000, with its current market cap around $7.67 billion.

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc. (NASDAQ:IBRX) confirmed the US Food and Drug Administration accepted for review the supplemental Biologics License Application (sBLA) for ANKTIVA Plus BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer. The supplemental BLA was accepted for […]

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best momentum stocks to buy according to analysts. ImmunityBio Inc. (NASDAQ:IBRX) announced on May 19 that the U.S. Food and Drug Administration accepted for review the supplemental Biologics License Application for ANKTIVA® in combination with Bacillus Calmette-Guerin to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary […]

ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's core Anktiva drug.

ImmunityBio Inc. on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory to develop, import, and commercialize the Tokyo strain of BCG for bladder cancer treatment in the U.S. ImmunityBio Secures Exclusive Rights To...

ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Is IBRX a good stock to buy? We came across a bullish thesis on ImmunityBio, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on IBRX. ImmunityBio, Inc.’s share was trading at $8.10 as of April 21st. ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and […]

ImmunityBio (IBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).